|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2001-12-0303.
NEOPLASIA
From INSERM 448 and Dermatology Department,
Faculté de Médecine de Créteil, Créteil,
France, and INSERM 532, Institut de Recherche sur la Peau, Paris,
France.
Extensive phenotype analysis of cutaneous T-cell lymphoma (CTCL)
malignant cell lines revealed surface expression of receptors usually
not detected on normal circulating CD4+CD45RO+
lymphocytes. We previously found that CTCL malignant cells express the
killer cell immunoglobulinlike receptor (KIR) KIR3DL2/CD158k, whereas
they fail to express the other KIRs. In the present study, we report
for the first time that the CD85j/immunoglobulin (Ig)-like transcript
2 (ILT2) receptor is found on Sézary cell lines and on
circulating Sézary malignant CD4+ cells, while it is
hardly detectable on circulating CD4+ lymphocytes from
healthy individuals. We demonstrate that ILT2 is functional on
CTCL cells, as its triggering leads to the recruitment of Src homology
2 domain-containing tyrosine phosphatase (SHP-1) and to the specific
inhibition of CTCL malignant cell proliferation induced by
CD3/T-cell receptor (TCR) stimulation. Interestingly, we found
that separated CD4+ILT2+ circulating malignant
Sézary cells are less susceptible to anti-CD3 monoclonal antibody
(mAb)-induced cell death than autologous
CD4+ILT2 Cutaneous T-cell lymphomas (CTCLs) are a
heterogeneous group of lymphoproliferative disorders of the
skin.1 The most frequent CTCLs, mycosis fungoides (MF) and
its leukemic counterpart Sézary syndrome (SS), are both
characterized by a clonal T-lymphocyte proliferation with a
CD4+CD45RO+ phenotype. While MF presents with a
skin-restricted infiltration of the clonal T-lymphocyte population and
an indolent course, SS is an aggressive form of CTCL.2,3
The factors that drive a T-cell clone to proliferate and to escape from
the immune control are not clearly understood. The pathogenic role of
viruses4-6; other epidermal cells, such as keratinocytes
and dendritic cells7,8; or aberrant secretion or response
to certain cytokines, such as transforming growth factor In an attempt to define specific cell surface receptors restricted to
CTCL that may elucidate the pathophysiology of the disease, we have
recently identified the expression of the unique inhibitory killer cell
Ig-like receptor (KIR) CD158k/KIR3DL2 on SS tumor cells.13
In normal peripheral blood lymphocytes (PBLs), only natural killer (NK)
cells and a subset of CD8+ memory cytolytic T lymphocyte
(CTLs) express KIR in a clonotypic manner. The interaction of
KIR with specific major histocompatibility complex (MHC)-I alleles
determines the NK cell tolerance to self and maintains CD8+
T lymphocyte survival.14-16
In the present study we further extended the phenotypic
characterization of Sézary cells. We report for the first time
that Sézary malignant cells express at their cell membrane an
increased level of the CD85j/Ig-like transcript 2 (ILT2)
molecule, which belongs to a family of receptors homologous to KIR and
encoded by genes located in the leukocyte receptor
complex.17-19 The ILT molecules have both inhibitory forms
recruiting SHP-1 and short-tailed activating forms.20 They
differ from KIRs in that they are mainly expressed on phagocytic and
antigen-presenting cells such as monocytes, macrophages, dendritic
cells, and B lymphocytes. Some inhibitory receptors, however, are
detected on peripheral NK and T lymphocytes.21 Interestingly, although it is detectable on the surface of a small proportion of CD8+ PBLs, ILT2 is present in the cytoplasm
of all circulating T cells.22 We found that CTCL malignant
cells express a significant amount of SHP-1 and that the latter is
recruited by ILT2 on cell stimulation. Further on, we demonstrate that
engagement of ILT2 surface molecule inhibits the anti-CD3 mAb-induced
proliferation of CTCL tumor cells, whereas it fails to inhibit the
proliferation induced by IL-7. These findings suggest that CTCL
malignant cells express on their surface functional inhibitory
receptors that interfere with signaling through CD3/TCRs. In addition,
we showed that malignant CD4+ILT2+ cells
separated from the blood of patients with SS are more resistant to
CD3/TCR-dependent activation-induced cell death than the normal autologous CD4+ lymphocytes, which fail to express
ILT2. Thus, the surface expression of KIR3DL2 and ILT2 on CTCL
constitutes a powerful tool for the identification of malignant
lymphocytes and for the study of the molecular basis of the disease.
Patients
Cells and cell lines
Monoclonal antibodies and flow cytometry studies Indirect immunofluorescent staining was performed with hybridoma supernatants or ascites fluid; fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse Ig (GAM) from Caltag laboratories (San Francisco, CA) was used. For 2-color analysis the immunofluorescent staining was performed by incubating 3 × 105 cells with anti-ILT2 mAb for 30 minutes at 4°C. Cells were then washed and further incubated with FITC-conjugated goat anti-mouse IgM + IgG (Caltag laboratories). After double washing, the free GAM binding sites were blocked with an excess of normal mouse Ig for 5 minutes at room temperature. Without further washing, the cells were incubated with a second phycoerythrin (PE)- or TriColor (TRI)-conjugated specific mAb. Stained cells were analyzed by means of a single argon flow cytometer analyzer (EPICS XL, Beckman-Coulter, Miami, FL), as described elsewhere.26 PE- or TRI-conjugated anti-CD3, anti-CD4, anti-T cell receptor variable (TCRV) 22, and anti-TCRV8 mAbs were
purchased from Immunotech (Marseilles, France); PerCP-Cy5.5-conjugated
anti-CD4 mAb was obtained from BD Biosciences (San Jose, CA); and the
anti-TCRV13 mAb was obtained from BIOadvance (Emerainville,
France). The mAb ICO-86 used as isotype control for SHP-1
coimmunoprecipitation studies was kindly provided by Anatoli Baryshikov
(N. N. Blokhin Cancer Research Center, Moscow, Russia). Anti-ILT2 mAbs
GHI/75 and VMP55 were obtained through the exchanges of the Fifth and Seventh International Workshops on Leukocyte Antigens. For
intracellular labeling, cells were fixed in phosphate-buffered saline
4% p-formaldehyde for 20 minutes at 4°C, washed, and then
permeabilized with staining buffer containing 0.1% saponin. The
sorting experiments were done with PBMCs from 2 SS patients with a
significant number of circulating Sézary cells ( 20% of PBLs).
Briefly, cells were labeled with anti-CD4 and anti-ILT2 GHI/75 mAb and
the CD4+ gated lymphocytes were sorted into
ILT2+ and ILT2 fractions with an EPICS Elite
cell-sorter (Beckman-Coulter). Separated cells were incubated for 9 hours with immobilized anti-CD3 mAbs or control mAb (10 µg/mL) and
labeled with FITC-conjugated annexin V (Pharmingen, San Diego, CA) for
10 minutes at room temperature. After washing, propidium iodide (PI)
(20 µg/mL) was added and the percentage of apoptotic cells was
determined on the basis of annexin V binding and PI exclusion
by means of a single argon flow cytometer analyzer (EPICS XL,
Beckman-Coulter).
Biochemical studies For the biochemical studies, 2 × 107 cells per sample for immunoprecipitation and 5 × 105 cells per sample for whole cell lysates were stimulated or not with 1 mM sodium vanadate and 0.03% H2O2 for 2 minutes at room temperature. Cells were washed in cold Tris-buffered saline and resuspended in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 1 mM Na pervanadate, 10 mM NaF, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 µg/mL aprotinin, and 1 µg/mL leupeptin) for 1 hour at 4°C. Postnuclear supernatant was then precleared for 1 hour at 4°C with 25 µL protein A-Sepharose beads per sample, and whole cell lysates were resolved by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Alternatively, cell lysates were subjected to immunoprecipitation with 5 µL of GHI/75 ascites or isotype-matched anti-CD4 ascite (ICO-86) for 1 hour followed by protein G-Sepharose beads for 2 hours at 4°C. Immunoprecipitates were washed 4 times with washing buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM Na pervanadate, 10 mM NaF, 1 mM PMSF), and precipitated proteins were subjected to SDS-PAGE and transferred to Hybond hydrophobic polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia, Orsay, France). Immunoblotting was performed with anti-SHP-1 polyclonal rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by horseradish peroxidase-conjugated goat anti-rabbit IgG and the enhanced chemiluminescence (ECL) detection system according to manufacturers' recommendations (Amersham Pharmacia).Messenger RNA (mRNA) analysis by reverse transcriptase-PCR Total RNA was extracted by means of the phenol-chloroform technique, and 3 µg of total RNA was reverse-transcribed according to Clontech (Palo Alto, CA) recommendations. Complementary DNA was amplified with ILT2- and G3PDH-specific primers with PCR (30 and 35 cycles), according to the described conditions.22 Samples were analyzed in a 1.5% agarose gel stained with ethidium bromide. The intensity of the bands was analyzed with Biorad Gel Doc 2000 (Biorad, Milan, Italy). Semiquantitative analysis was performed by comparing the intensity of ILT2-specific fluorescence in healthy and Sézary patients. For immunoscope analysis, the technique has been described in detail elswhere.27,28Proliferation assays For proliferation assays, 5 × 104 cells were cultured in triplicate in 96-well round-bottomed plates (Greiner, Nürtingen, Germany) in a final volume of 0.2 mL of culture medium. For stimulation of the Pno cell line, plates were precoated with anti-CD3 mAb (1 µg/well). Cells were cultured for 4 days and were pulsed with 1 µCi (0.037 MBq) of 3H[TdR] during the last 8 to16 hours of culture. Incorporation of 3H[TdR] was measured in a liquid scintillation counter (Topcount, Packard Instrument, Meriden, CT).
CTCL cell lines are stained by anti-ILT2 mAb We have previously described 2 cytokine-dependent long-term CD4+ CTCL tumor cell lines, Cou-L (TCRV13+)
and Pno (TCRV22+), that were derived from circulating
tumor T lymphocytes.24,25 We have demonstrated by
phenotypic and genetic analysis that both cell lines were identical to
the malignant cells found in the patients' blood and skin. While not
expressing most of the established Ig-like and lectinlike killer cell
inhibitory receptors, both cell lines were reactive, with monoclonal
antibodies recognizing p140/KIR3DL2.13 We
extended the phenotypic analysis of these CTCL cell lines with the
anti-ILT2 mAbs GHI/75 and VMP55 and established that both cell lines
expressed ILT2 molecules on their surfaces (Figure
1). Interestingly, as reported with
normal T-cell clones,22 the levels of ILT2 surface
expression on both malignant cell lines varied considerably in the
course of a standard in vitro culture (data not shown).
Circulating Sézary malignant cells express ILT2 Previous results indicated that the ILT2 molecule was practically not detectable on CD4+ circulating lymphocytes22 (see control in Figure 3), whereas it was found on the cell surfaces of lymphocytes after in vitro stimulation and on IL-2-dependent CD4+ T cell clones. Therefore, it was important to determine whether the expression of ILT2 on the CTCL malignant cell lines was not attributable to their in vitro expansion with cytokines. We tested the surface expression of ILT2 with the GHI/75 mAb on freshly isolated PBLs from 4 untreated SS patients previously studied by immunoscope analysis for the TCRV usage of the
expanded malignant clone (Ingen-Housz-Oro et al, manuscript in
preparation). We found ILT2 on the surface of tumor cells in 4 of 4 patients studied. Figure 2A shows results
obtained with 2 of these patients in which the malignant cells
exhibited a significant level of TCR molecules detectable by flow
cytometry. In both patients the profile of anti-ILT2 mAb binding to
TCRV8+ cells corresponded to a weak homogeneous
expression by the whole malignant clonal cell population. It should be
noted that ILT2 cell membrane expression appeared to be restricted to
circulating CD4+ SS malignant lymphocytes, as
CD4+ lymphocytes isolated from involved skin of patients
with pagetoid reticulosis or MF failed to exhibit at their membranes
detectable levels of ILT2 molecules (Figure 2B).
We further tested freshly isolated PBLs from 8 SS patients with
cytomorphological data for blood involvement and established an
increased ILT2 expression on the CD4+ subset (Figure
3) as compared with healthy control
individuals (control, Figure 3). It should be noted, however, that
individual variations in the intensity of ILT2 surface labeling existed
between the patients, independent of the percentage of morphologically detected malignant cells.
Expression of ILT2-specific mRNA in PBLs from SS patients is not increased As normal T lymphocytes were reported to express significant amounts of ILT2 in their cytoplasm, it was important to determine whether the surface expression of ILT2 on CD4+ CTCL cells reflected an increased traffic from the intracellular compartments rather than an enhancement of the transcriptional activity.22 To clarify this issue, we compared, as described elsewhere,22 the levels of specific-ILT2 mRNA in the PBLs of 4 patients with a dominant CD4+ Sézary cell clone (> 50% of PBLs) with levels in 4 healthy controls who had only a small subset of CD8+ lymphocytes bearing a surface expression of ILT2. The results (Figure 4A) revealed no significant differences in the level of specific ILT2 mRNA between the 2 groups. Interestingly, this lack of difference in the expression of ILT2 mRNA between healthy individuals and SS patients was correlated with the lack of difference in the intracellular anti-ILT2 mAb staining obtained in the 2 groups (Figure 4B).
CTCL cell lines express SHP-1 that is recruited by ILT2 on cell activation Engagement of ILT2 induces tyrosine-phosphorylation of the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which subsequently recruit SHP-1 phosphatases that dephosphorylate adaptors involved in TCR signaling.29 However, lack or dysfunction of SHP-1 was reported to be frequent in T-cell lymphoma cell lines.12 To determine whether the ILT2 receptors that we detected in CTCL malignant cell lines could exhibit inhibitory function, we studied the expression of SHP-1 protein in Pno and Cou-L cells. SHP-1 was detected in both cell lines, and its expression was equivalent to that in normal phytohemagglutinin (PHA)-activated PBLs (Figure 5A). Next, to determine whether ILT2 molecules recruited SHP-1 phosphatase on phosphorylation, we immunoprecipitated ILT2 from Pno cells, either unstimulated or stimulated with sodium pervanadate (the latter inducing substantial tyrosine phosphorylation of cellular substrates), and studied the precipitates for the presence of SHP-1. We found that ILT2 was constitutively associated with SHP-1 and that this association significantly increased after pervanadate treatment (Figure 5B). Finally, to demonstrate that ILT2 expressed by CTCL malignant cells can deliver a negative signal sufficient to inhibit cell proliferation, we studied the functional consequence of ILT2 molecule engagement on Pno CTCL cells triggered to proliferate through their CD3/TCR receptors. We have previously demonstrated that immobilized anti-CD3 mAb induced a weak but significant proliferation of Pno cells. Figure 5C shows that the cross-linking of ILT2 receptors (with their specific mAb followed by GAM Ig) resulted in a significant decrease in the proliferation rate of CTCL cells triggered by immobilized anti-CD3 mAb. Interestingly, the cross-linking of ILT2 receptors alone did not influence the IL-7-dependent proliferation of Pno malignant cells (Figure 5C).
ILT2+ circulating Sézary cells are resistant to CD3/TCR-dependent activation-induced cell death To study the difference in survival ability following CD3/TCR engagement between freshly isolated CD4+ Sézary cells and normal autologous CD4+ lymphocytes, we used cell sorting to separate CD4+ILT2+ and CD4+ILT2 subpopulations from the blood of
patients with significant numbers of circulating Sézary cells.
Figure 6 shows representative results obtained with 2 of 4 patients studied. The experiment presented in
Figure 6A was performed with PBMCs from the previously described patient Cou, expressing 30% of CD4+TCRV13+
circulating malignant cells.24 We verified with the
anti-TCRV13 mAb that the CD4+ILT2+ isolated
lymphocytes corresponded to the malignant Sézary cells (data not
shown). The sorted fractions were then stimulated for 9 hours with an
immobilized anti-CD3 mAb or an isotype-matched control mAb, followed by
labeling with annexin V and PI. We found that the malignant
CD4+ILT2+ population was less sensitive to
anti-CD3 mAb-induced cell death than the CD4+ normal
population (Figure 6A, lower panel). Similar results were obtained with
a different patient, expressing 20% of
CD4+ILT2+ malignant cells (Figure 6B). It must
be noted that almost no annexin V-positive cells were obtained when
both sorted populations were incubated with the isotype control mAb
(Figure 6, shaded histograms).
ILT2 is an inhibitory receptor specific for a broad range of MHC class Ia and Ib molecules and the viral class I-like protein UL18.30,31 All myeloid and B lymphocytes and a subset of NK lymphocytes express ILT2. In addition, this molecule along with KIR is expressed by peripheral CD8+ T cells with memory/effector phenotype.32 According to previous studies with the anti-ILT2 mAb GHI/75, most circulating CD4+ lymphocytes fail to express ILT2 on their cell surfaces, whereas the molecule is present in the cytoplasm of all T cells, including the CD4+ subpopulation.22 This broad expression reflects a key role in the negative regulation of important immune functions, including antigen presentation, antigen- and superantigen-driven activation, and generation of effector and memory T cells.20,33 We previously demonstrated that CD4+ CTCL malignant cells express KIR3DL2/CD158k, while lacking expression of the other killer cell inhibitory receptors, including the lectinlike molecules.13 In addition, we recently reported an apparently novel molecule expressed at the cell surface of circulating Sézary cells, which provides inhibitory signals to CD3/TCR engagement of CTCL malignant cells.34 The present study addresses for the first time the expression of ILT2
in patients with CD4+ SS malignant cells. Initially, we
established the surface expression of ILT2 in cytokine-dependent
CD4+ malignant T-cell lines. Because ILT2 surface
expression increases during lymphocyte activation and has been reported
on all CD4+ T-cell clones studied,22 it was
important to confirm our observation with peripheral circulating
Sézary cells. Indeed, ILT2 was detected on the cell membrane of
peripheral blood Sézary cells that were distinguished from normal
reactive CD4+ lymphocytes with the appropriate anti-TCRV Previous studies established a constitutive activation of the IL-2R Janus kinase-signal-transducing activator of transcription (Jak-STAT) signaling pathway in a number of malignant T-cell lines as a possible explanation for their uncontrolled growth.39,40 Further, a lack of expression of the SHP-1 phosphatase due to extensive methylation of its gene promoter was recently reported in T-cell lymphomas as a possible explanation for the persistent activation of IL-2R/Jak and other signaling pathways.12 Considering that SHP-1 is essential for the generation of negative signals through ILT2, it might be speculated that the overexpression of ILT2 in Sézary cells simply reflects deficient ILT2/SHP-1 signaling. Unexpectedly, however, we detected the SHP-1 protein in both CTCL cell lines studied, and it was quantitatively identical to the amounts of SHP-1 found in normal PBLs (Figure 5A). A persistence of IL-2R/Jak3 phosphorylation in the presence of SHP-1 had already been observed in few malignant T-cell lines and it was supposed that the SHP-1 protein expressed in CTCL cells was not functional.40 In the present study we demonstrated that in vitro phosphorylation of ILT2 molecules on tumor cells effectively results in the recruitment of SHP-1. Moreover, the ILT2/SHP-1 pair was functional, since the engagement of ILT2 by its specific mAb inhibited the anti-CD3-induced tumor cell line proliferation. The results we obtained with CTCL are similar to those reported for normal T cells in which cross-linking of ILT2 inhibits CD3-induced intracellular Ca++ mobilization and the proliferation of CD4+ T cells.22 The existence of a functional ILT2 inhibitory pathway in CTCL does not preclude the constitutive IL-2R/Jak phosphorylation, because, according to our results, ILT2 does not interfere with cytokine receptor signaling. SHP-1 may not be available to IL-2R because it has already been recruited by inhibitory receptors. Indeed, we observed not only recruitment but also a basal level of SHP-1/ILT2 association (Figure 5B), which has not been reported for normal ILT2+ cells.20,29 It has already been noted that TCR signaling in CTCL tumor cells is reduced, along with decreased activity of Zap70, Syk, and membrane Csk.41 Our results suggest that this deficiency may result at least in part from the overexpression of functional ILT2 inhibitory receptors. Finally, we found that circulating malignant Sézary cells may be separated from the nonmalignant reactive CD4+ autologous T lymphocytes by means of anti-ILT2 mAb GHI/75. We found that these malignant cells, as compared with the autologous reactive CD4+ lymphocytes, are resistant to anti-CD3 mAb-induced cell death. These results suggest that CD4+ CTCL resistance to activation-induced cell death is associated with the expression of inhibitory receptors, as has been already reported for normal circulating effector or memory CD8+ T cells expressing ILT2 and KIR.32 In conclusion, the expression of functional inhibitory signaling molecules may perpetuate survival of CTCL malignant cells by protecting them from activation-induced apoptosis following CD3/TCR engagement. Furthermore, cytokines such as IL-7 were found to maintain the survival of CTCL by increased expression of bcl-2.25,42 Thus, malignant Sézary cells exhibit receptors capable of inhibiting signaling through TCR, whereas these receptors do not inhibit proliferation induced by cytokines. These results are in agreement with the finding that IL-7 overexpression in transgenic mice causes cutaneous lymphomas.43,44 Finally, the identification of functional receptors expressed on CTCL malignant cells constitutes an important step toward an understanding of the molecular basis of the disease and the elaboration of novel therapeutic approaches.
Submitted December 21, 2001; accepted March 29, 2002.
Prepublished online as Blood First Edition Paper, April 30, 2002; DOI 10.1182/blood-2001-12-0303.
Supported by grants from INSERM, Paris, France, Association de la Recherche contre le Cancer, Villejuif, France, and GEFLUC, Ivry sur Seine, France.
M.N. and P.M. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Armand Bensussan, INSERM 448, Faculté de Médecine de Créteil, 8 rue du Général Sarrail, 94010 Créteil, France; e-mail: armand.bensussan{at}im3.inserm.fr.
1.
Willemze R, Kerl H, Sterry W, et al.
EOTRC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
Blood.
1997;90:354-371 2. Jahn S, Asadullah K, Walden P, Sterry W. Cutaneous malignant lymphomas. Immunol Today. 1998;19:100-103[CrossRef][Medline] [Order article via Infotrieve].
3.
Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM.
Primary cutaneous T-cell lymphoma: review and current concepts.
J Clin Oncol.
2000;18:2908-2925 4. Zucker-Franklin D. The role of human T cell lymphotropic virus type I tax in the development of cutaneous T-cell lymphoma. Ann N Y Acad Sci. 2001;941:86-96[Medline] [Order article via Infotrieve]. 5. Shimakage M, Sasagawa T, Kawahara K, Yutsudo M, Kusuoka H, Kozuka T. Expression of Epstein-Barr virus in cutaneous T-cell lymphoma including mycosis fungoides. Int J Cancer. 2001;92:226-231[CrossRef][Medline] [Order article via Infotrieve]. 6. Nagore E, Ledesma E, Collado C, Oliver V, Perez-Perez A, Aliaga A. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T and B cell lymphomas. Br J Dermatol. 2000;143:320-323[CrossRef][Medline] [Order article via Infotrieve]. 7. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci. 2001;941:1-11[CrossRef][Medline] [Order article via Infotrieve]. 8. Dummer R, Willers J, Kamarashev J, Urosevic M, Dobbeling U, Burg G. Pathogenesis of cutaneous lymphomas. Semin Cutan Med Surg. 2000;19:78-86[Medline] [Order article via Infotrieve].
9.
Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM.
Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T cell lymphomas.
Clin Diagn Lab Immunol.
1999;6:79-84 10. Daliani D, Ulmer RA, Jackow C, et al. Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. Leuk Lymphoma. 1998;29:315-328[Medline] [Order article via Infotrieve]. 11. Asadullah K, Docke WD, Haeussler A, Sterry WA, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol. 1996;107:833-837[CrossRef][Medline] [Order article via Infotrieve].
12.
Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik YA.
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Am J Pathol.
2000;157:1137-1146
13.
Bagot M, Moretta A, Sivori S, et al.
CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor.
Blood.
2001;97:1388-1391 14. Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immune Rev. 1997;155:145-154. 15. Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev. 1997;155:105-117[CrossRef][Medline] [Order article via Infotrieve]. 16. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T lymphocytes: a safety mechanism which may impair protective T-cell responses. Immunol Today. 1998;19:153-157[CrossRef][Medline] [Order article via Infotrieve]. 17. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol. 1997;27:660-665[Medline] [Order article via Infotrieve]. 18. Mason D, Andre P, Bensussan A, et al. CD antigens 2001. Eur J Immunol. 2001;31:2841-2847[CrossRef][Medline] [Order article via Infotrieve]. 19. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity. 2001;15:363-374[CrossRef][Medline] [Order article via Infotrieve]. 20. Allan DS, McMichael AJ, Braud VM. The ILT family of leukocyte receptors. Immunobiology. 2000;202:34-41[Medline] [Order article via Infotrieve].
21.
Colonna M, Navarro F, Bellon T, et al.
A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.
J Exp Med.
1997;186:1809-1818
22.
Saverino D, Fabbi M, Ghiotto F, et al.
The CD85/ LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
J Immunol.
2000;165:3742-3755
23.
Delfau-Larue MH, Dalac S, Lepage E, et al.
Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
Blood.
1998;92:3376-3380
24.
Bagot M, Echchakir H, Mami-Chouaib F, et al.
Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T cell clones infiltrating a cutaneous T-cell lymphoma.
Blood.
1998;91:4331-4341
25.
Poszepczynska E, Bagot M, Echchakir H, et al.
Functional characterization of an IL-7-dependent CD4+ CD8 26. Schiavon V, Elhabazi A, Agrawal S, et al. G10.3 monoclonal antibody identifies novel functional cell surface structures expressed by normal B lymphocytes and various malignant cell lines. Tissue Antigens. 1999;53:23-32[CrossRef][Medline] [Order article via Infotrieve].
27.
Musette P, Bachelez H, Flageul B, et al.
Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of limited number of T cell clones.
J Immunol.
1999;162:1789-1794 28. Pannetier C, Levraud JP, Lim A, Even J, Kourilsky P. The immunoscope approach for the analysis of T cell repertoires. In: Oksenberg JR, ed. Protocols and applications. New York, NY: Chapman & Hall; 1998:287-325.
29.
Dietrich J, Cella M, Colonna M.
Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization.
J Immunol.
2000;166:2514-2521 30. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol. 1999;29:277-283[CrossRef][Medline] [Order article via Infotrieve]. 31. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homologue UL18. Immunity. 1999;11:603-613[CrossRef][Medline] [Order article via Infotrieve].
32.
Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P.
Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL.
J Immunol.
2001;166:3933-3941 33. Borges LM, Hsu N, Fanger L, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol. 1997;159:5192-5196[Abstract]. 34. Nikolova M, Tawab A, Marie-Cardine A, Bagot M, Boumsell L, Bensussan A. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. J Invest Dermatol. 2001;116:731-738[Medline] [Order article via Infotrieve].
35.
Casado LF, Granados E, Algara P, Navarro F, Martinez-Frejo MF, Lopez-Botet M.
High expression of the ILT2 (LIR-1) inhibitory receptor for major histocompatibility complex class I molecules on clonal expansions of T large granular lymphocytes in asymptomatic patients.
Haematologica.
2001;86:457-463 36. Asadullah K, Friedrich M, Docke WD, Jahn S, Volk HD, Sterry W. Enhanced expression of T-cell activation and natural killer cell antigens indicates anti-tumor response in early cutaneous T-cell lymphoma. J Invest Dermatol. 1997;108:743-747[CrossRef][Medline] [Order article via Infotrieve]. 37. Stefanato CM, Tallini G, Crotty PL. Histologic and immunophenotypic features prior to transformation in patients with transformed cutaneous T-cell lymphoma: is CD25 expression in skin biopsy predictive of large cell transformation in cutaneous T-cell lymphoma? Am J Dermatopathol. 1998;20:1-6[CrossRef][Medline] [Order article via Infotrieve]. 38. Salamone MDC, Salamone GV, Reyes GB, et al. CD85 workshop: CD85 antigen: an activation marker of human T cells. In: Kishimoto T,Kikutani H,von dem Borne AEGK, et al., eds. Leukocyte Typing VI. Oxford, England: Oxford University Press; 1997:200-201.
39.
Ward AC, Touw I, Yoshimura A.
The Jak-Stat pathway in normal and perturbed hematopoiesis.
Blood.
2001;95:19-29
40.
Zhang Q, Nowak I, Vonderheid EC, et al.
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Proc Natl Acad Sci U S A.
1996;93:9148-9153 41. Fargnoli MC, Edelson RL, Berger CL, et al. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk, and membrane-associated Csk. Leukemia. 1997;11:1338-1346[CrossRef][Medline] [Order article via Infotrieve].
42.
Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U.
Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.
Blood.
2001;98:2778-2783
43.
Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P.
Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice.
J Exp Med.
1993;177:305-316 44. Williams IR, Rawson EA, Manning L, Karaoli T, Rich BE, Kupper TS. IL-7 overexpression in transgenic mouse keratinocytes causes a lymphoproliferative skin disease dominated by intermediate TCR cells. J Immunol. 1997;159:3044-3056[Abstract].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C.-D. Klemke, D. Brenner, E.-M. Weiss, M. Schmidt, M. Leverkus, K. Gulow, and P. H. Krammer Lack of T-Cell Receptor-Induced Signaling Is Crucial for CD95 Ligand Up-regulation and Protects Cutaneous T-Cell Lymphoma Cells from Activation-Induced Cell Death Cancer Res., May 15, 2009; 69(10): 4175 - 4183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kirwan and D. N. Burshtyn Killer Cell Ig-Like Receptor-Dependent Signaling by Ig-Like Transcript 2 (ILT2/CD85j/LILRB1/LIR-1) J. Immunol., October 15, 2005; 175(8): 5006 - 5015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tenca, A. Merlo, E. Merck, E. E. M. Bates, D. Saverino, R. Simone, D. Zarcone, G. Trinchieri, C. E. Grossi, and E. Ciccone CD85j (Leukocyte Ig-Like Receptor-1/Ig-Like Transcript 2) Inhibits Human Osteoclast-Associated Receptor-Mediated Activation of Human Dendritic Cells J. Immunol., June 1, 2005; 174(11): 6757 - 6763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ikehara, S. K. Ikehara, and J. C. Paulson Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9 J. Biol. Chem., October 8, 2004; 279(41): 43117 - 43125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van Doorn, R. Dijkman, M. H. Vermeer, J. J. Out-Luiting, E. M. H. van der Raaij-Helmer, R. Willemze, and C. P. Tensen Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sezary Syndrome Identified by Gene Expression Analysis Cancer Res., August 15, 2004; 64(16): 5578 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saverino, F. Ghiotto, A. Merlo, S. Bruno, L. Battini, M. Occhino, M. Maffei, C. Tenca, S. Pileri, L. Baldi, et al. Specific Recognition of the Viral Protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T Cells Mediates the Non-MHC-Restricted Lysis of Human Cytomegalovirus-Infected Cells J. Immunol., May 1, 2004; 172(9): 5629 - 5637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Urosevic, J. Kamarashev, G. Burg, and R. Dummer Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2 Blood, March 1, 2004; 103(5): 1796 - 1798. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(IFN
both with a TCRV
